Decolonization of carbapenem-resistant *Klebsiella pneumoniae* from the intestinal microbiota of model mice by phages targeting two surface structures

Ju-Yun Liu¹,², Tzu-Lung Lin¹, Ching-Yu Chiu¹, Pei-Fang Hsieh¹, Yi-Tsung Lin³, Li-Yin Lai³ and Jin-Town Wang¹,⁴*  

¹Department of Microbiology, College of Medicine, National Taiwan University, Taipei City, Taiwan,  
²National Laboratory Animal Center, National Applied Research Laboratories Research Institute, Taipei City, Taiwan,  
³Department of Medical Research, Taipei Veterans General Hospital, Taipei City, Taiwan,  
⁴Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan  

**Background:** *Klebsiella pneumoniae* is a normal component of the human gastrointestinal tract microbiota. However, in some cases, it can cause disease. Over the past 20 years, the prevalence of antibiotic-resistant bacteria, such as carbapenem-resistant *K. pneumoniae* (CRKP), has been increasing.

**Materials and methods:** We attempted to specifically eliminate CRKP from a mouse model with the human intestinal microbiota. To establish humanized microbiota-colonized mice, we administered K64 CRKP-containing human microbiota to germ-free mice by fecal microbiota transplantation. Then, we used two phages, one targeting the capsule (ϕK64-1) and one targeting O1 lipopolysaccharide (ϕKO1-1) of K64 *K. pneumoniae*, to eliminate CRKP.

**Results:** In untreated control and ϕKO1-1-treated K64-colonized mice, no change in CRKP was observed, while in mice treated with ϕK64-1, a transient reduction was observed. In half of the mice treated with both ϕKO1-1 and ϕK64-1, CRKP was undetectable in feces by PCR and culture for 60 days. However, in the other 50% of the mice, *K. pneumoniae* was transiently reduced but recovered 35 days after treatment.

**Conclusion:** Combination treatment with ϕK64-1 and ϕKO1-1 achieved long-term decolonization in 52.3% of mice carrying CRKP. Importantly, the composition of the intestinal microbiota was not altered after phage treatment. Therefore, this strategy may be useful not only for eradicating drug-resistant bacterial species from the intestinal microbiota but also for the treatment of other dysbiosis-associated diseases.

**Keywords**  
carbapenem-resistant *K. pneumoniae* (CRKP), phage treatment, microbiota, decolonization, receptor
Background

Phages are viruses that infect bacteria, and lytic phages can lyse and kill bacteria. Therefore, they were used for the treatment of bacterial infections before the discovery of antibiotics. Due to its narrow spectrum, it was not commonly used after antibiotic days. It is now used only for special conditions that are difficult to treat with antibiotics (Kortright et al., 2019). Klebsiella pneumoniae is a normal component of the upper respiratory and gastrointestinal tract microbiota in humans (Bowers et al., 2016). However, under some circumstances, it can cause disease. It can cause community-acquired pneumonia, urinary tract infection (UTI), wound infection, and, recently, pyogenic liver abscess (PLA) and necrotizing fasciitis (Fang et al., 2007; Rahim et al., 2019). The increasing prevalence of antibiotic resistance determinants, such as extended-spectrum β-lactamase (ESBL), in K. pneumoniae, is a serious problem, and recent global surveillance data from Europe, Asia, and North and South America revealed that the prevalence of ESBL-producing K. pneumoniae was 7.5–44% (Reinert et al., 2007). Moreover, the prevalence of carbapenem-resistant K. pneumoniae (CRKP) has been dramatically increasing worldwide (Srinivasan and Patel, 2008; Hidron et al., 2009; Sisto et al., 2012; Chiu et al., 2013). Drug-resistant K. pneumoniae strains are part of the normal intestinal flora (Bowers et al., 2016), and fecal carriage of CRKP can predispose patients to nosocomial CRKP infections when their immune systems become weakened or impaired (Falagas et al., 2014). Thus, the decolonization of CRKP from the gut of hospitalized patients could prevent CRKP infections (Septimus and Schweizer, 2016). However, antibiotic-mediated decolonization has been reported to be associated with the development of resistance, and selection for resistant Gram-negative organisms (Saidel-Odes et al., 2012; Septimus and Schweizer, 2016). Programmable, sequence-specific antimicrobials using RNA-guided nuclease Cas9 (Gasiunas et al., 2012; Jinek et al., 2012) delivered by a bacteriophage have been developed to reduce a specific strain in microbiota. Both methods reduced the concentration of the target strains in vitro and in vivo; however, the effects were transient. It has been improved by using phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. However, this method also needs genetic deletion of the target strain besides applying phages (Lam et al., 2021). With the growing knowledge of microbiome, phages are also used to manipulate gut microbiome because its specificity compared with those of antibiotics and cause less change in microbiota. However, the effects are also transient, either by a single phage or multiple phage combinations. An in vitro study showed that phage resistance bacteria appeared more frequently if the combination of multiple phages targeting a same receptor (Hesse et al., 2020). In addition, we found isolating phages with wild type K. pneumoniae almost all targeting capsules. Therefore, we isolated a phage targeting the lipopolysaccharide (LPS) from a capsule deletion mutant. We chose the most prevalent capsule type of CRKP in Taiwan and tried a combination of two phages targeting capsule and LPS in K. pneumoniae to eliminate K. pneumoniae in intestinal colonization. To mimic the human intestinal microbiome, we also used a humanized microbiota animal by transplanting a patient’s microbiota to germ-free mice.

Materials and methods

Human stool collection and isolation and characterization of Klebsiella pneumoniae strains

Stool specimens were collected from a patient hospitalized in Taipei Veterans General Hospital with a CRKP infection and CRKP colonization in 2013 (Pan et al., 2013). The K. pneumoniae strains present in the specimens were isolated on Eosin Methylene Blue (EMB) agar plates. Their capsular type was determined by wzc sequencing (Pan et al., 2013) and confirmed by wzy PCR genotyping (Pan et al., 2015). Primer pairs are listed in Table 1. PCR amplifications were performed with the Long and Accurate PCR system (Takara, Tokyo, Japan). The cycling program was 96°C for 3 min, followed by 30 temperature cycles of 96°C for 30 s, 46°C for 15 s, and 72°C for 3 min. Drug susceptibility was assessed using a Vitek 2 system.

Additionally, we tested mice colonized with human microbiota free of K. pneumoniae then added K64 CRKP at the beginning. The results were similar. Therefore, the latter model was not used.

Bacteriophage isolation and preparation

Bacteriophages were isolated from untreated water or soil. The agar overlay method was used for phage isolation, to obtain a pure preparation, and for titer determination. A high-titer phage preparation was generated by amplification and purification using the confluent lysis method as previously described (Lin et al., 2014).

In Taiwan, K64 was the most prevalent capsular type of CRKP (Pan et al., 2015). Therefore, we chose K64 for this decolonization test. To isolate a phage specific for K64 K. pneumoniae from the natural environment, a K. pneumoniae strain with K64 type capsule was co-inoculated with sewage collected in Taipei City in LB broth overnight. After centrifugation, the supernatant was filtered using a 0.45 µm filter and spotted onto LB plates overlaid with the K. pneumoniae K64 strain to detect phage plaques. An agar overlay method
was used for the isolation of a pure phage preparation and
to determine phage titer. Single plaque isolation, elution, and
re-plating were performed repeatedly. The pure isolate of this
phage lyzed the K64 type of *K. pneumoniae* strains efficiently
and named as ϕK64-1 (Pan et al., 2017). Capsule type was
determined by PCR using primers specific for the K64 wzy
gene and confirmed by sequencing. The efficiency of bacterial
killing was assessed by using a phage killing assay. Survivors that
were resistant to this phage were isolated. Then, the efficiency
of bacterial killing by bacteriophage mixtures was examined as
previously described (Pan et al., 2017). Actually, all CRKP strains
with the K64 capsule type were sensitive to the ϕK64 type of
*K. pneumoniae* isolated in this study.

We had repeatedly screened phages using wild-type *K. pneumoniae* strains with K1 and K64 capsule types yielded only phages targeting the capsule. To obtain phages that targeted other bacterial surface structures, we constructed a capsule-negative strain by generating a *magA* deletion mutant of NTUH-K2044 on which O1 type LPS was exposed. Screening for phages that infect this mutant yielded a phage, ϕKO1-1 (Hsieh et al., 2014), that targets O1 LPS.

**In vitro phage killing assay**

Phage killing assays were done as previously described with minor modifications (Mateus et al., 2014). Briefly, bacteria (1 × 10^4 CFU) were incubated with phage (1 × 10^2, 1 × 10^5, 1 × 10^7 PFU; i.e., MOI = 10, 10^2, 10^3) at 37°C for 30 min. Then, the surviving bacteria were enumerated by plating serial dilutions and determining the CFU, and the survival ratio was calculated.

**Establishment of a humanized intestinal microbiota mouse model**

Fecal samples were collected from a patient carrying capsular type K64 CRKP. Then, samples were aliquoted in fresh
conditions and stored at -80°C until use. To mimic possible future human inoculations (Sarker et al., 2016), this human-derived fecal microbiota was diluted with saline ten times and
orally administrated to 7-week-old germ-free C57BL/6 mice
(Hong et al., 2016). The colonization of capsular type K64 CRKP in the mice was confirmed by PCR (Table 1) and real-time PCR (Figure 1).

The mice were bred and housed in germ-free isolation
operation boxes within the animal care facility of the National Taiwan University College of Medicine (NTUCM) and the Laboratory Animal Center at the National Laboratory Animal Center (NLAC). The time course of animal experiments is shown in Figure 2.

**Stool deoxyribonucleic acid extraction, *Klebsiella pneumoniae* detection, and microbiota analysis**

DNA was extracted from stool samples using the QIAamp DNA Stool Mini Kit (Qiagen) according to the manufacturer’s protocol. *K. pneumoniae* was detected by PCR, real-time PCR, and confirmed by culture. Real-time PCR amplifications were performed with Power SYBR® Green Master Mix (REF: 4367659). The cycling program was 95°C for 30 s, followed by 45 temperature cycles of 95°C for 5 s and 60°C for 30 s. Primer pairs that targeted *wzy* and *wzc* genes are listed in Table 1. The composition of the microbiota in the established mouse model was determined by the 16s rDNA sequencing. Briefly, the full-length16S was amplified by PCR using the V1–V9 region of the 16S rRNA gene primers 27F/1492R (Johnson et al., 2019). Then, the amplicons were purified by using the GeneJET Gel Extraction Kit (Thermo Scientific) and quantified using the Qubit dsDNA HS Assay Kit (Qubit) on a Qubit 2.0 Fluorometer (Qubit). Amplicons were purified using PCR purification kits (Qiagen) according to the manufacturer's protocol.

DNA was extracted from stool samples using the QIAamp DNA Stool Mini Kit (Qiagen) according to the manufacturer’s protocol. *K. pneumoniae* was detected by PCR, real-time PCR, and confirmed by culture. Real-time PCR amplifications were performed with Power SYBR® Green Master Mix (REF: 4367659). The cycling program was 95°C for 30 s, followed by 45 temperature cycles of 95°C for 5 s and 60°C for 30 s. Primer pairs that targeted *wzy* and *wzc* genes are listed in Table 1. The composition of the microbiota in the established mouse model was determined by the 16s rDNA sequencing. Briefly, the full-length16S was amplified by PCR using the V1–V9 region of the 16S rRNA gene primers 27F/1492R (Johnson et al., 2019). Then, the amplicons were purified by using the GeneJET Gel Extraction Kit (Thermo Scientific) and quantified using the Qubit dsDNA HS Assay Kit (Qubit) on a Qubit 2.0 Fluorometer (Qubit). Amplicons were purified using PCR purification kits (Qiagen) according to the manufacturer's protocol.

**Table 1** Primsers used in this study.

| Primer name     | Sequence                       | Purpose               | Target gene |
|-----------------|--------------------------------|-----------------------|-------------|
| KP-wzc-CR1      | TTCAGCTGGATTTTGTTGG            | PCR and sequencing    | wzc         |
| KP-wzc-CR2      | GCTCCATCATTTGCAAAAATG          | PCR and sequencing    | wzc         |
| K64 wzyF new    | CTTTAGGCTGCTACGCC              | PCR genotyping        | wzy         |
| K64 wzyR new    | CGGGGCGCAGG AACATTAG           | PCR genotyping        | wzy         |
| K64 wzy F new   | AACAGTGGCTATTCTTGTAGTGG        | real-time PCR         | wzy         |
| K64 wzy R new   | AATACCCCAAATAAACCCAAATCGA      | real-time PCR         | wzy         |
Phage treatment for the elimination of carbapenem-resistant *Klebsiella pneumoniae* in model mice

Germ-free mice were orally inoculated with human GI-tract microbiota containing K64 *K. pneumoniae* (diluted 100-fold). The mice were divided into five groups 1 week after the models were established: the control group (no phage treatment, group I, *n* = 4); group II (*n* = 4), which was inoculated orally with ϕK64-1; group III, which was inoculated orally with ϕKO1-1 (*n* = 4); group IV, which was inoculated orally with both ϕKO1-1 and ϕK64-1 (*n* = 28); and group V, which was inoculated orally and injected intraperitoneally with both ϕKO1-1 and ϕK64-1 (*n* = 16). The mice were treated with 1 × 10⁹ PFU/mice of bacteriophage (ϕKO1-1, ϕK64-1, or both) via intragastric injection one time a day for 3 days (day 1, day 3, and day 5).
Since mice are coprophilous animals, each mouse was housed in a separate individually ventilated cage (IVC). No cage floors were used in this study. We collected fecal samples just before phage treatment (day 1) and at 7, 14, 21, 28, 35, and 56 days after the first day of phage treatment. DNA isolated from the stool samples was used to detect K64 \textit{K. pneumoniae} by PCR and real-time PCR, and \( \phi \text{KO1-1} \) and \( \phi \text{K64-1} \) were detected by real-time PCR.

Results

Isolation of the \textit{Klebsiella pneumoniae} bacteriophages \( \phi \text{K64-1} \) and \( \phi \text{KO1-1} \)

The fresh stool specimen of the patient colonized with K64 type \textit{K. pneumoniae} was aliquoted and frozen at -80\(^\circ\)C in 2013 until use. The humanized microbiota was established by inoculating diluted frozen aliquoted samples from the patient to germ-free mice (Vandeputte et al., 2017).

The multi-host \textit{K. pneumoniae} bacteriophage \( \phi \text{K64-1} \), which can infect K1, K11, K21, K25, K30, K35, K64, and K69 reference strains, was previously isolated. The genome sequence, which was determined by high-throughput sequencing, was 346,602 bp in length and contained multiple depolymerases (Pan et al., 2017). A second phage, \( \phi \text{KO1-1} \), was isolated that infected acapsular \textit{K. pneumoniae} strains which contain O1 LPS but not capsular strains (Hsieh et al., 2012).

\textbf{In vitro killing of K64-type \textit{Klebsiella pneumoniae} strains by \( \phi \text{K64-1} \) and \( \phi \text{KO1-1} \)}

The killing effects of \( \phi \text{K64-1} \) and \( \phi \text{KO1-1} \) alone and in combination on two K64-type \textit{K. pneumoniae} strains, CB-0001 and S84, were first assessed in vitro. At a multiplicity of infection (MOI) of 1,000, 100 and 10, phage \( \phi \text{K64-1} \) killed the majority...
TABLE 2  Intestinal CRKP colonization of mice in each treatment group.

| Group (n) | Phage treatment | D0  | D7  | D14 | D21 | D35 | D56 |
|-----------|-----------------|-----|-----|-----|-----|-----|-----|
| I (4)*    | None            | +   | +   | +   | +   | +   | +   |
| II (4)*   | ϕKO1-1          | +   | -   | -   | +   | +   | +   |
| III (4)*  | ϕK64-1          | +   | -   | -   | +   | +   | +   |
| IV (28)*  | ϕKO1-1 and ϕK64-1 orally | +   | -   | -   | +   | +   | +   |
| V (16)*   | ϕKO1-1 and ϕK64-1 orally and intraperitoneally | +   | -   | -   | +   | +   | +   |

CRKP, carbapenem-resistant *K. pneumoniae.*
*Total number of mice in each group.
+ CRKP detected by polymerase chain reaction (PCR).
− CRKP negative by PCR and culture.
D, days post phage treatment.

of the K64 bacteria. The survivors after phage killing (i.e., insensitive to K64-1) were capsule negative strains that formed relatively non-mucoid colonies and were negative for alcian blue staining (data not shown). However, these non-capsulated survivors could be killed by ϕKO1-1, which targets the O1 antigen of LPS (Fang et al., 2004). Although ϕKO1-1 could not infect wild-type K64 strains with intact capsule, the combination of ϕK64-1 and ϕKO1-1 at MOIs of 1,000 and 100 killed all of the K64 bacteria. However, complete killing achieved only in half of the *in vitro* tests with MOI = 10 (Figure 3A). The survivors after *in vitro* phage killing were all non-capsuled. The wild type was susceptible to phage K64-1, while non-capsuled mutants were resistant to phage K64-1 and sensitive to phage KO1-1 (Figure 3B). The spot tests had been repeated for more than 5 times and showed the same picture.

**Bacteriophage treatment of humanized intestinal microbiota model mice**

The *K. pneumoniae* detection assay results by real-time PCR in 6 mice are shown in Figure 1. The average number of *K. pneumoniae* in all untreated humanized microbial flora model mice was 3,480 ± 473 CFU/g (Figure 1A). Negative real-time PCR results also showed negative PCR results. Therefore, the results of PCR and real-time PCR were consistent.

After the treatment of ϕ K64-1 and ϕKO1-1, ϕK64-1 reached a peak on the 7 days after treatment, with an average of 26,669 ± 18,717 PFU/g, and the average number on the 14 days would drop to 753 ± 538 PFU/g, and it was almost undetectable at 56 days (Figure 1B). However, ϕO1-1 reached an average of 82,976 ± 9,553 PFU/g on the 7 days after treatment, increased to an average of 87,839 ± 6,224 PFU/g on the 14 days, and continued to increase thereafter, reaching an average of 125,125 ± 18,676 PFU/g at 56days (Figure 1C). No phage was detected from day 0 to 56 in the control group (not shown).

**Changes in the microbiota composition after phage treatment**

Results of 16S rDNA sequencing were uploaded to NCBI, PRJNA766775.

The prevalence of *K. pneumoniae* in humanized mice ranged from 0.01 to 0.09% before phage treatments, while the prevalence ranged from 0.04 to 0.08% 56 days after failed treatments. Shannon’s diversity index is commonly used to characterize species diversity in a community. Germ-free mice were orally inoculated with human GI-tract microbiota, so Shannon’s diversity index was highest before treatment (SD0). The difference then become lower at SD14 and SD56 (Figure 4A).

1 https://www.ncbi.nlm.nih.gov/sra/PRJNA766775
FIGURE 3
Killing of two K64 K. pneumoniae strains by two bacteriophages. (A) Killing effects of two bacteriophages in two K64 K. pneumoniae strains, CB-0001 and S84. Bacteria were incubated with buffer (control), phage ϕK64-1, or phages ϕK64-1 and ϕKO1-1 (MOI = 10, 100, and 1,000) overnight. Then, bacterial survival was calculated by comparison to the initial counts and is shown as the mean ± standard deviation [SD] from three independent experiments. **p < 0.01 by Student’s t-test (compared with control). ND, none detected. (B) Phenotype and susceptibility of K64 parental strains and non-capsulated survivors. (Top) Phenotypic differences in the hyper-mucoid phenotypes of the parental and non-capsulated survivor strains on LB agar. (Bottom) Spot tests of phages ϕK64-1 and ϕKO1-1 (10^8 PFU) on the K64 parental and non-capsulated survivor strains.

The Firmicutes/Bacteroidetes (F/B) ratio is widely accepted to have an important influence in maintaining normal intestinal homeostasis. Increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed with obesity, and the latter with inflammatory bowel disease (IBD; Stojanov et al., 2020). The F/B ratio was the highest before phage treatment (SD0). However, there was no significant difference between SD14 and SD56, and it fell below 0.5 at D56, indicating that the GI-tract microbiota might gradually return to balance (Figure 4B).

Spot tests for carbapenem-resistant Klebsiella pneumoniae survived after combination phage treatments

Carbapenem-resistant K. pneumoniae were isolated from mouse feces after 56 days of phage treatment failed mice, and were confirmed as K64 by PCR (data not shown). We observed that, in contrast to the in vitro killing assays, the isolated CRKP could still be infected by ϕK64-1 by plaque assay (Figures 5A,B). The amount of ϕK64-1 was the highest after 7 days of phage treatment, but it was decreased by more than 1 × 10^4 times after 14 days of phage treatment (Figure 1B).

Discussion

Our previous survey revealed that K64 was the most prevalent CRKP type in Taiwan; therefore, we chose K64 type K. pneumoniae as the model strain in this study. Our results showed that treatment with phage ϕK64-1 only transiently suppressed the K64 strains. This result agreed with previous findings in phage treatment studies. However, 52.3% of the mice in the combination treatment group achieved long-term (56 days) decolonization of
FIGURE 4
Changes in the intestinal microbiota composition before and after treatment with phages ϕK64-1 and ϕKO1-1 for the removal of CRKP. (A) Shannon’s diversity index. SD0 had the highest species diversity, and then species diversity gradually decreases. There was no significant difference between the SD14 and Fail groups. (B) Firmicutes/Bacteroidetes ratio. The F/B ratio of Fail, SD0, and SD7 groups were greater than 0.5, and there was no significant difference between the SD14 and SD56 groups. S: CRKP cannot be detected by PCR after phage treatment. Fail: CRKP detected by PCR after phage treatment. D: days post phage treatment.

K64 CRKP as shown by PCR and culture. In the other 47.7% of mice, K. pneumoniae reappeared at 3 weeks after treatment, indicating transient suppression (for about 2 weeks), which was similar to that observed with the ϕK64-1 treatment alone. A recent study found that the administration of a cocktail of three bacteriophages to LF82-colonized CEABAC10 transgenic mice significantly but transiently (for several weeks) decreased the number of adherent-invasive Escherichia coli (AIEC) in feces and the adherent flora of intestinal sections (Galtier et al., 2017). In our in vitro assay, capsule-negative mutant strains appeared immediately after ϕK64-1 treatment. Since phage screening using wild-type K. pneumoniae only identified phages targeting capsules (Hsieh et al., 2012; Pan et al., 2017), combinations of naturally selected phages fail to kill mutants with a single outer surface change.

Although fecal microbiota transplantation has been used to successfully eradicate drug-resistant strains (Davido et al., 2017; Feehan and Garcia-Diaz, 2020), the potential side effects make this method less satisfactory. In addition, the procedures
are more tedious than combination phage therapy. Failure of the combination treatment may be due to an inadequate of ϕK64-1 dosage. In our in vitro studies, no mutants resistant to both ϕKO1-1 and ϕK64-1 were detected. However, long-term clearance of CRKP was not achieved in half of the mice. Phage K64-1 is specific to K64, so when K64 was reduced and phage K64-1 decrease rapidly (Figure 1B). It may be the reason why K64 cannot be completely eliminated. O1 polysaccharides in GI-tract microbiota will be recognized by phage O1, so the number of phage O1 was still maintained (Figure 1C). In two mice that failed to colonize, CRKP detected in 1 or 2 weeks (Figure 1A). Quantification by 16S rDNA, Proteobacteria decreased by about 50% after phage treatment and remained stable until day 56. The titers of ϕK64-1 were very low by real-time PCR. It may be caused by experimental procedures or individual mice difference. This may be due to the limited stomach volume of mice, which allowed a maximum dose of $1 \times 10^9$ PFU by oral inoculation. If this is the case, oral inoculation for more than 3 days may achieve a higher decolonization rate in mice. In human, higher doses of inoculation may also achieve higher successful rates.

One side effect of using antibiotic treatment to suppress a bacterial species in the intestine is alteration of the microbiota composition. The combination phage treatment used in our study seemed to cause fewer changes in the microbiota during and after treatment, and the F/B ratio seemed generally returned to pre-treatment status by 2 months after treatment. This suggests that this strategy not only has the potential to be used to reduce or eliminate drug-resistant Enterobacteriaceae but also has a great potential for the treatment of other bacterial species associated with dysbiosis and systemic-related diseases.

In conclusion, treatment with the combination of two bacteriophages, ϕK64-1 and ϕKO1-1, achieved long-term decolonization of CRKP in 52.3% of model mice carrying CRKP. The intestinal microbiota largely was not altered by the phage treatment. These data indicate that this strategy may be useful for not only eradicating drug-resistant bacterial species from the intestinal microbiota but also for the treatment of dysbiosis-associated diseases.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

Author contributions

J-TW and J-YL designed the study, analyzed the data, and revised the manuscript. J-YL, C-YC, and Y-TL prepared materials and performed the experiments. J-YL, T-LL, and P-FH analyzed the data. J-YL, T-LL, L-YL, and P-FH wrote the main text of the manuscript. All the authors reviewed and approved the final version of the manuscript.

Funding

This study was supported by the Ministry of Science and Technology, the National Taiwan University, the National Taiwan University Hospital of Taiwan, and the Liver Disease Prevention and Treatment Research Foundation of Taiwan. "Center of Precision Medicine" from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
et al. (2017). Bacteriophages targeting adherent invasive Escherichia coli causing pyogenic liver abscess. doi: 10.3389/fmicb.2022.877074

Liu et al. (2017). A programmable dual-RNA-guided DNA endonuclease as a promising new treatment for Crohn’s disease. J Crohns Colitis 11, 840–847. doi: 10.1093/ecto/jcw224

Falagas, M. E., Tsenarli, G. S., Karageorgopoulos, D. E., and Vardakas, K. Z. (2014). Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg. Infect. Dis. 20, 1170–1175. doi: 10.3201/eid2007.121104

Fang, C. T., Lai, S. Y. Y., Wu, C. T., Huang, Y. P., Liu, K. L., and Chang, S. C. (2007). Klebsiella pneumoniae genotype K1. An emerging pathogen that causes septic oesal or central nervous system complications from pyogenic liver abscess. Clin. Infect. Dis. 45, 284–293. doi: 10.1086/519262

Fang, C. T., Chuang, Y. P., Shun, C. T., Chang, S. C., and Wang, J. T. (2004). A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J. Exp. Med. 199, 697–705. doi: 10.1084/jem.20030857

Falagas, M. E., Baxevani, A., Halaris, A. E., and Pappas, G. (2012). Carbapenem non-susceptible Klebsiella pneumoniae: Implication in typing and treatment. J. Infect. Dis. 215, 174–1744. doi: 10.1093/infdis/jiu332

Mature, L., Costa, L., Silva, Y., Pereira, C., Cunha, A., and Almeida, A. (2014). Efficiency of phage cocktails in the inactivation of Vibrio in aquaculture. Aquaculture 424-425, 167–173. doi: 10.1016/j.aquaculture.2014.01.001

Pan, Y. J., Lin, T. L., Chen, C. C., Tsai, Y. T., Cheng, Y. H., Chen, Y. Y., et al. (2017). KlebSeq, a diagnostic tool for surveillance, detection, and monitoring of Klebsiella pneumoniae. Proc. Natl. Acad. Sci. U.S.A. 114, 29, 1107–1109. doi: 10.1073/pnas.1611161114

Pal, S., Bandyopadhyay, A., Das, T., and Maiti, S. (2014). Capsular types of Klebsiella pneumoniae: Revisited by wzc sequencing. PLoS One 9, 11808. doi: 10.1371/journal.pone.011808

Srinivasan, A., Patel, J. B. (2008). Klebsiella pneumoniae carbapenemase-producing organisms: An ounce of prevention really is worth a pound of cure. Infect. Control Hosp. Epidemiol. 29, 1107–1109. doi: 10.1086/594129

Stojanov, S., Berlec, A., and Strükel, B. (2020). The influence of probiotics on the ferrimics/bacteroides ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms 8, 1715. doi: 10.3390/microorganisms8111715

Vanpeutte, D., Tito, R. Y., Vanleeuwen, R., Falony, G., and Raes, J. (2017). Practical considerations for large-scale gut microbiome studies. FEMS Microbol. Rev. 41, S134–S167. doi: 10.1093/femsre/fux027